Back to Search
Start Over
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
- Source :
- Global Data Point. April 20, 2024
- Publication Year :
- 2024
-
Abstract
- (GlobeNewswire) - Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a study [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Global Data Point
- Publication Type :
- News
- Accession number :
- edsgcl.790837394